行情

DARE

DARE

Dare Bioscience
NASDAQ

实时行情|Nasdaq Last Sale

1.750
+0.080
+4.79%
盘后: 1.710 -0.04 -2.29% 16:14 09/21 EDT
开盘
1.700
昨收
1.670
最高
1.760
最低
1.690
成交量
216.31万
成交额
--
52周最高
3.850
52周最低
0.9447
市值
1.23亿
市盈率(TTM)
-2.1675
分时
5日
1月
3月
1年
5年
Dare Bioscience 参加 HC Wainwright 第 23 届年度全球投资大会
Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright 23rd Annual Global Investment ...
GlobeNewswire · 09/08 12:00
敢生科技参与女性健康创新峰会圆桌讨论
The discussion, Women's Health Case Study: Optimizing Study Enrollment During the COVID-19 Pandemic, will review the DARE-BVFREE Phase 3 study that was successfully initiated and completed during 2020
GlobeNewswire · 09/07 12:00
Daré Bioscience 将出席第 13 届欧洲更年期和男性更年期大会
Presentation will highlight the positive topline results from the Phase 1 clinical trial of DARE-HRT1 Study results demonstrate DARE-HRT1’s ability to co-deliver two different active pharmaceutical ingredients reliably over a 28-day period SAN DIEGO, Sept....
GlobeNewswire · 09/01 12:00
BRIEF-Daré Bioscience Reports Q2 Loss Per Share Of $0.18
reuters.com · 08/12 12:27
Dare Bioscience Q2 每股收益 $(0.18) 低于 $(0.16) 估计
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 33.33 percent increase over losses of $(0.27) per share from
Benzinga · 08/12 12:20
The Daily Biotech Pulse:Xeris 启动甲状腺功能亢进症研究,Merck-Eisai Snag FDA 对药物组合的批准,Jazz Pharma 的决定日
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
预计 2021 年 8 月 12 日的收益
  Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Benzinga · 08/12 08:14
由于细菌性阴道病候选药物获得 FDA 优先审查,Dare Bioscience 股票的交易价格更高
Benzinga · 08/09 15:21
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解DARE最新的财务预测,通过DARE每股收益,每股净资产,每股现金流等数据分析Dare Bioscience近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测DARE价格均价为5.40,最高价位11.00,最低价为3.000。
EPS
机构持股
总机构数: 34
机构持股: 338.31万
持股比例: 4.80%
总股本: 7,052.20万
类型机构数股数
增持
10
80.13万
建仓
8
20.85万
减持
4
89.97万
平仓
6
34.60万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.35%
制药与医学研究
+0.70%
高管信息
Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Secretary/Director
Sabrina Johnson
Chief Financial Officer
Gregg Beloff
Chief Financial Officer
Lisa Walters-Hoffert
Chief Accounting Officer/Controller/Treasurer
Jame O'Neill
Other
John Fair
Director
Sophia Ononye-Onyia
Independent Director
Cheryl Blanchard
Independent Director
Jessica Grossman
Independent Director
Steve Hall
Independent Director
Susan Kelley
Independent Director
Gregory Matz
Independent Director
Robin Steele
暂无数据
DARE 简况
Dare Bioscience Inc是一家临床阶段的生物制药公司。该公司专注于开发女性健康产品。其差异化疗法组合扩大了治疗选择,改善了结果并为女性在避孕、阴道健康、性健康和生育领域提供了便利。其产品线包括三种处于临床晚期开发阶段的候选产品、三种处于I期临床开发阶段的候选产品和三种处于临床前开发阶段的候选产品。其在研产品包括DARE-BV1、Ovaprene、Sildenafil Cream, 3.6%、DARE-HRT1、DARE-FRT1、DARE-VVA1、DARE-LARC1、ORB-204和ORB-214以及DARE-RH1。DARE-BV1专注于治疗细菌性阴道病。Ovaprene旨在提供多周的避孕保护,以及处于临床开发后期阶段的Sildenafil Cream, 3.6%,用于治疗女性性唤起障碍。

微牛提供Dare Bioscience Inc(NASDAQ-DARE)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的DARE股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易DARE股票基本功能。